Figure 4.
Loss of SAP-Fyn signaling pathway does not greatly alter AITL-like disease. (A) Abrogation of downstream signaling between SAP and Fyn kinase does not prevent tumor incidence, but may have a partial effect (n = 17 Roquinsan/+; Sh2d1a+/y and n = 29 Roquinsan/+; Sh2d1aR78A/y). (B-E) Tumors from Roquinsan/+; Sh2d1a+/y or Roquinsan/+; Sh2d1aR78A/y show comparable T-B-cell expression patterns and frequencies (n = 3 Roquinsan/+; Sh2d1a+/y tumors and n = 7 from Roquinsan/+; Sh2d1aR78A/y tumors). Error bars in panels B-E represent the SEM. Data are pooled from at least 2 independent experiments. **P < .01.

Loss of SAP-Fyn signaling pathway does not greatly alter AITL-like disease. (A) Abrogation of downstream signaling between SAP and Fyn kinase does not prevent tumor incidence, but may have a partial effect (n = 17 Roquinsan/+; Sh2d1a+/y and n = 29 Roquinsan/+; Sh2d1aR78A/y). (B-E) Tumors from Roquinsan/+; Sh2d1a+/y or Roquinsan/+; Sh2d1aR78A/y show comparable T-B-cell expression patterns and frequencies (n = 3 Roquinsan/+; Sh2d1a+/y tumors and n = 7 from Roquinsan/+; Sh2d1aR78A/y tumors). Error bars in panels B-E represent the SEM. Data are pooled from at least 2 independent experiments. **P < .01.

Close Modal

or Create an Account

Close Modal
Close Modal